NASDAQ:SRLS - SeraCare Life Sciences Stock Price, Price Target & More

Previous CloseN/A
Today's RangeN/A
52-Week RangeN/A
Average VolumeN/A
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A

About SeraCare Life Sciences (NASDAQ:SRLS)

SeraCare Life Sciences, Inc. (SeraCare) serves the global life sciences industry by providing products and services to facilitate the discovery, development and production of human and animal diagnostics and therapeutics. The Company's portfolio includes diagnostic controls, plasma-derived reagents and molecular biomarkers, bio banking and contract research services. It operates two segments: Diagnostic and Biopharmaceutical Products, and BioServices. The Diagnostic & Biopharmaceutical Products segment includes two types of products: controls and panels. The Bio Services segment includes bio banking, sample processing and testing services for research and clinical trials, and contract research services in molecular biology, virology, immunology and biochemistry.

Receive SRLS News and Ratings via Email

Sign-up to receive the latest news and ratings for SRLS and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry N/A


Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A


Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A


EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net MarginsN/A
Return on EquityN/A
Return on AssetsN/A


Outstanding SharesN/A

How to Become a New Pot Stock Millionaire

SeraCare Life Sciences (NASDAQ:SRLS) Frequently Asked Questions

What is SeraCare Life Sciences' stock symbol?

SeraCare Life Sciences trades on the NASDAQ under the ticker symbol "SRLS."

Who are some of SeraCare Life Sciences' key competitors?

Has SeraCare Life Sciences been receiving favorable news coverage?

Press coverage about SRLS stock has been trending somewhat positive recently, Accern Sentiment Analysis reports. The research group scores the sentiment of media coverage by analyzing more than twenty million blog and news sources. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. SeraCare Life Sciences earned a media sentiment score of 0.20 on Accern's scale. They also gave news headlines about the company an impact score of 45.38 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the company's share price in the next several days.

How do I buy shares of SeraCare Life Sciences?

Shares of SRLS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How can I contact SeraCare Life Sciences?

SeraCare Life Sciences' mailing address is 37 Birch St, MILFORD, MA 01757-5501, United States. The company can be reached via phone at +1-508-2446400.

MarketBeat Community Rating for SeraCare Life Sciences (SRLS)

Community Ranking:  2.3 out of 5 (star star)
Outperform Votes:  28 (Vote Outperform)
Underperform Votes:  32 (Vote Underperform)
Total Votes:  60
MarketBeat's community ratings are surveys of what our community members think about SeraCare Life Sciences and other stocks. Vote "Outperform" if you believe SRLS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe SRLS will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

SeraCare Life Sciences (NASDAQ:SRLS) Analyst Ratings History

DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
(Data available from 4/22/2016 forward)


SeraCare Life Sciences (NASDAQ:SRLS) Earnings History and Estimates Chart

Earnings by Quarter for SeraCare Life Sciences (NASDAQ:SRLS)

SeraCare Life Sciences (NASDAQ SRLS) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
2/10/2012Q1 2012$0.04$0.07ViewN/AView Earnings Details
11/17/2011Q4 2011$0.02($0.04)ViewN/AView Earnings Details
7/26/2011Q3 2011$0.07$0.03ViewN/AView Earnings Details
5/12/2011Q2 2011$0.06$0.07ViewN/AView Earnings Details
2/11/2011Q1 2011$0.08$0.04ViewN/AView Earnings Details
12/1/2010Q4 2010$0.08$0.11ViewN/AView Earnings Details
8/11/2010Q3 2010$0.12$0.07ViewN/AView Earnings Details
4/29/2010Q2 2010$0.09$0.11ViewN/AView Earnings Details
2/9/2010Q1 2010$0.07ViewN/AView Earnings Details
11/19/2009Q4 2009$0.08ViewN/AView Earnings Details
8/11/2009Q3 2009$0.04ViewN/AView Earnings Details
5/12/2009Q2 2009($0.03)ViewN/AView Earnings Details
2/17/2009Q1 2009($0.10)ViewN/AView Earnings Details
12/8/2008Q4 2008($0.56)ViewN/AView Earnings Details
5/15/2008Q2 2008($0.02)ViewN/AView Earnings Details
2/14/2008Q1 2008($0.04)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)


SeraCare Life Sciences (NASDAQ:SRLS) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

SeraCare Life Sciences (NASDAQ SRLS) Insider Trading and Institutional Ownership History

Insider Trading History for SeraCare Life Sciences (NASDAQ:SRLS)

SeraCare Life Sciences (NASDAQ SRLS) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
(Data available from 1/1/2013 forward)


SeraCare Life Sciences (NASDAQ SRLS) News Headlines

No headlines for this company have been tracked by

SEC Filings

SeraCare Life Sciences (NASDAQ:SRLS) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media


SeraCare Life Sciences (NASDAQ:SRLS) Income Statement, Balance Sheet and Cash Flow Statement


SeraCare Life Sciences (NASDAQ SRLS) Stock Chart for Sunday, April, 22, 2018

Loading chart…

This page was last updated on 4/22/2018 by Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.